Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

Leggi l'articolo originale


Journal of Clinical Oncology, Ahead of Print.

Lascia un commento